Answers are grounded in this paper and cite their sources.
Li-Fraumeni syndrome (LFS), caused by germline TP53 mutations, predisposes to a wide spectrum of malignancies, but an association with pituitary tumors has not been definitively established. We performed germline sequencing on 20 patients with aggressive pituitary tumors. Pathogenic/likely pathogenic variants were identified in three patients: one high-penetrant variant, TP53 (NM_000546) c.799C>T (p.Arg267Trp), and two low-penetrant variants that are likely incidental findings: LZTR1 (NM_006767) c.1214delG (p.Gly405Alafs*56) and MUTYH (NM_001128425) c.536A>G (p.Tyr179Cys). The patient diagnosed with LFS presented in her 20s with an aggressive, silent corticotroph pituitary tumor that progressed within 5 months of the initial subtotal transsphenoidal resection. Molecular analysis identified biallelic inactivation of TP53 and widespread chromosomal loss-of-heterozygosity (cLOH) involving 8 of the 12 chromosomes frequently lost in aggressive corticotroph tumors with somatic TP53 mutations. Biallelic TP53 inactivation and the presence of cLOH supports that the germline TP53 mutation functions as a driver.
No takes yet. Share an insight, caveat, or question.
Theodorou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: